71 related articles for article (PubMed ID: 10333165)
1. Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial.
Huber MT; Gotthardt U; Schreiber W; Krieg JC
Pharmacopsychiatry; 1999 Mar; 32(2):68-72. PubMed ID: 10333165
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial.
Müller MJ; Gründer G; Wetzel H; Müller-Siecheneder F; Marx-Dannigkeit P; Benkert O
Psychiatry Res; 1999 Dec; 89(3):275-80. PubMed ID: 10708274
[TBL] [Abstract][Full Text] [Related]
3. Open clinical trial on the sigma ligand panamesine in patients with schizophrenia.
Frieboes RM; Murck H; Wiedemann K; Holsboer F; Steiger A
Psychopharmacology (Berl); 1997 Jul; 132(1):82-8. PubMed ID: 9272763
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study.
Modell S; Naber D; Holzbach R
Pharmacopsychiatry; 1996 Mar; 29(2):63-6. PubMed ID: 8741023
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Results of an open clinical study.
Klimke A; Klieser E
Pharmacopsychiatry; 1991 Jul; 24(4):107-12. PubMed ID: 1684439
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
Möller HJ; Pelzer E; Kissling W; Riehl T; Wernicke T
Pharmacopsychiatry; 1991 Nov; 24(6):185-9. PubMed ID: 1725925
[TBL] [Abstract][Full Text] [Related]
7. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
Potkin SG; Litman RE; Torres R; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S4-11. PubMed ID: 18334911
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
Buckley PF
Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
[TBL] [Abstract][Full Text] [Related]
11. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology and treatment of negative symptoms.
Villeneuve A
Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S53-8. PubMed ID: 7533052
[TBL] [Abstract][Full Text] [Related]
13. Amoxapine as an antipsychotic: comparative study versus haloperidol.
Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
[TBL] [Abstract][Full Text] [Related]
15. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Gibel A; Ritsner MS
Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
17. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
Lee KU; Jeon YW; Lee HK; Jun TY
Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
[TBL] [Abstract][Full Text] [Related]
19. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
[TBL] [Abstract][Full Text] [Related]
20. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
